Nov. 10, 2005 – Dendritic Nanotechnologies and Lumera announced that they have entered into a joint research agreement to co-develop proprietary surface chemistries suitable for specific applications of Lumera’s label-free array reader, ProteomicProcessor.

Dendritic is a Mount Pleasant, Mich., company focused on the discovery, development, and commercialization of dendrimer technologies to create new of products for the identification and treatment of human diseases. Lumera Corp. is a Bothell, Wash., firm that designs proprietary molecular structures and polymer compounds for the bioscience and communications and computing industries. The company also has developed proprietary processes for fabricating such devices.

Under the terms of the agreement, Dendritic will build chemistries on proprietary Lumera surfaces, focusing efforts on using their expertise and patent holdings in the area of dendrimers. Lumera will use their proprietary instrument designs and biological systems to test and evaluate the dendrimer-based approaches. The companies expect to find performance features and benefits for proteomic applications.